2017年上半年美国FDA批准的新分子实体与评价:消化系统疾病、风湿病、感染性疾病和血液系统疾病治疗用药被引量：1

Updates of New Molecular Entities Approved by the FDA in the First-Half of 2017: Drugs for Gastrointestinal Disorders, Rheumatoid Arthritis, Skin Infections and Venous Thromboembolism

下载PDF

导出

摘要 2017年上半年,FDA批准了23个新药,其中新分子实体16种新生物制品7种。神经系统、肿瘤和皮肤病治疗药物获批数量位居前三位。本系列文章将对这些新药进行介绍和评价,本文将介绍消化系统疾病、风湿病、感染性疾病和血液系统疾病治疗新药。 The US FDA approved 23 new molecular entities and new therapeutic biological products in the first-half of 2017. This article provides an update and evaluation of the new drugs approved for the treatment of gastrointestinal disorders, rheumatoid arthritis, skin infections and venous thromboembolism.

作者孙树森赵志刚

机构地区美国西新英格兰大学药学与健康科学学院首都医科大学附属北京天坛医院药学部

出处《药品评价》 CAS 2018年第2期7-10,共4页 Drug Evaluation

关键词 FDA 2017年上半年新分子实体消化系统疾病风湿病感染性疾病血液系统疾病 FDA 2017 New Molecular Entity Gastrointestinal Disorders Rheumatoid Arthritis Skin Infections Venous Thromboembolism

分类号 R97 [医药卫生—药品]

引文网络
相关文献

参考文献2

1孙树森,马翔,韩容,赵志刚.2014年美国FDA批准的新分子实体与评价:消化系统疾病,神经系统疾病,银屑病和罕见病治疗用药以及造影剂[J].药品评价,2015,12(6):6-12. 被引量：6
2孙树森,韩容,赵志刚.2015年上半年美国FDA批准的新分子实体与评价:心血管系统疾病和癌症治疗用药[J].药品评价,2015,12(16):6-12. 被引量：9

二级参考文献42

1奈妥吡坦,中自洛诺司琼药品说明书[OL].Akynzeowebsite,,https://www.akynzeo.com/media/Prescribing-Information.pdf,2014-40-30/2015,1-6.
2Schwartzberg L. Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting[J]. Expert Rev Pharmacoecon Outcomes Res, 2014, 14(6): 825-834.
3Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancerpain[J]. N Engl J Med Overseas Ed, 2014, 370(25): 2387-2396.
4Garnock-Jones KP. Naloxegol: a review of its use in patients withopioid-induced constipation[J]. Drugs,2015,75(4):419-425.
5Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med Overseas Ed, 2013, 369(8): 699-710.
6Sandborn W J, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease[J]. N Engl J Med Overseas Ed, 2013, 369(8): 711-721.
7Sands BE, Feagan BG, Rutgeerts P, et aL Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed[J]. Gastroenterology, 2014, 147(3): 618-627.e3.
8Smith MA, Mohammad RA. Vedolizumab: an alpha4beta7 integrin inhibitor for inflammatory bowel diseases[J]. Ann Pharmacother, 2014, 48(12): 1629-1635.
9Connor K, Budd K, Snavely D, et al. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial(trial #l)[J]. JOURNAL OF SLEEP RESEARCH, 2012, 2I: 97-97.
10lvgy-May N, Leibensperger H, Froman S, et al. Efficacy and safety of suvorexant, an urexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial(trial #2)[J]. JOURNAL OF SLEEP RESEARCH, 2012, 21: 351-352.